MedPath

Effect of single dose dexamethasone on variation in Blood Glucose level in pediatric hypospadias surgery: A Prospective Randomised controlled study in department of Anesthesia, SMS Medical college, Jaipur

Not yet recruiting
Conditions
Hypospadias, unspecified,
Registration Number
CTRI/2023/10/058560
Lead Sponsor
Sawai Man Singh Medical College
Brief Summary

After obtaining Institutional Ethics Committee approval and written informed consent, 72 patients fulfilling inclusion criteria and undergoing elective surgery for hypospadias will be included.

Patient satisfying inclusion criteria and Pre anesthetic check up(PAC) fitness will be selected and taken into OT. Patient will be identified and informed written consent will be checked. Randomization will be done using opaque sealed envelope method. All monitors will be attached and baseline vitals will be recorded. Baseline blood sugar will be recorded and Glycopyrrolate(5ug/kg) Midazolam (0.05mg/kg) and Fentanyl (2ug/kg) will be administered to the patient via already secured I.V. line. Induction of the patient will be done using I.V. propofol 2mg/kg and I.V. atracurium(0.5mg/kg) to facilitate endotracheal intubation to secure airway  in every patient. Now, Group A will be administered single dose of dexamethasone(0.15mg/kg) and Group B  will be given saline through prefilled 5ml syringes that the anesthesiologist administering will not know about because of the blinding process. Post that, the patient will be put to left  lateral position and under all aspetic preacautions ,painting and draping will be done at and around the caudal block site, and caudal block will be administered to the patient using ropivacaine (0.2%) in dose 0.5 ml/kg. Blood glucose will be recorded 2 hours after administering dexamethasone. Maintainence of anesthesia will be done by oxygen, nitrous oxide and sevoflurane.  At the end of surgery, all the anesthetic agents will be discontinued and patient will be taken on 100% oxygen. Reversal of neuromuscular block will be done by I.V. neostigmine(0.05 mg/kg) and I.V. Glycopyrrolate (0.01mg/kg). On regain of adequate muscle power ,extubation will be done and the patient will be shifted to recovery room.

Post surgery ,patient will be assessed at regular time points for post-operative pain (using FLACC score), nausea,vomiting,fever,surgical site infection. Fasting blood sugar and post-prandial blood sugar will be recorded upto 72 hours of post-operative period.

Detailed Description

Not available

Recruitment & Eligibility

Status
Not Yet Recruiting
Sex
Male
Target Recruitment
72
Inclusion Criteria
  • Children (3-6 years) undergoing hypospadias surgery.
  • Parents/caretaker willing to consent for participation.
  • Patients belonging to American society of Anesthesiologists (ASA) grade I and II.
Exclusion Criteria
  • Patients with Diabetes Mellitus.
  • Patients on immunosuppressive /steroid therapy.
  • Patients with known allergy to dexamethasone.
  • Patients with hepatorenal dysfunction.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
To evaluate & compare the difference, in change in blood glucose levels at various time points in dexamethasone v/s control group.Baseline(pre_operative), | 2 hours after administration of dexamethasone/saline, | Fasting blood sugar and Post prandial blood sugar on : | Post_operative day: 1,2 and 3.
Secondary Outcome Measures
NameTimeMethod
1. To assess & compare the difference in mean no of doses & total doses of rescue analgesic needed in post-operative period upto 12 hours in both the groups.2. To assess & compare the difference in proportion of patients who experienced post-operative nausea, vomiting upto 12 hours in both the groups.

Trial Locations

Locations (1)

J.K. LON HOSPITAL, Affiliated to SMS Medical College, Jaipur

🇮🇳

Jaipur, RAJASTHAN, India

J.K. LON HOSPITAL, Affiliated to SMS Medical College, Jaipur
🇮🇳Jaipur, RAJASTHAN, India
Dr Neelam Dogra
Principal investigator
9928709289
Neelam_dogra24@yahoo.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.